Boehringer Ingelheim says may sell U.S. generics

January 15, 2015 10:14 AM

9 0

FRANKFURT (Reuters) - German drugmaker Boehringer Ingelheim said it is considering the sale of its U.S.-based generics unit Roxane Labs to put a stronger focus on the development and sale of new pharmaceuticals.

Unlisted Boehringer said in a statement on Thursday it was exploring strategic options, including a sale, for the Columbus, Ohio-based business, but no decision had been made yet.

Also read: GE cuts cost outlook for industrial unit after talks with Trian

Read more

To category page

Loading...